Mira announces acceptance of second Ketamir-2 manuscript for publication

MIRA Pharmaceuticals (MIRA) announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology. The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA’s first publication characterizing Ketamir-2’s clean pharmacology and favorable safety profile and align with the Company’s plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025. Key Findings from the Publication Chung Model: Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable benefit. Female rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory responses. Paclitaxel-Induced Neuropathy in Mice Gabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent relief. Efficacy Across Genders and Species Despite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested.